Matches in SemOpenAlex for { <https://semopenalex.org/work/W3194528984> ?p ?o ?g. }
- W3194528984 endingPage "2150" @default.
- W3194528984 startingPage "2140" @default.
- W3194528984 abstract "Abstract Monotherapy with PARP inhibitors is effective for the subset of castrate-resistant prostate cancer (CRPC) with defects in homologous recombination (HR) DNA repair. New treatments are required for the remaining tumors, and an emerging strategy is to combine PARP inhibitors with other therapies that induce DNA damage. Here we tested whether PARP inhibitors are effective for HR-proficient CRPC, including androgen receptor (AR)-null tumors, when used in combination with CX-5461, a small molecule that inhibits RNA polymerase I transcription and activates the DNA damage response, and has antitumor activity in early phase I trials. The combination of CX-5461 and talazoparib significantly decreased in vivo growth of patient-derived xenografts of HR-proficient CRPC, including AR-positive, AR-null, and neuroendocrine tumors. CX-5461 and talazoparib synergistically inhibited the growth of organoids and cell lines, and significantly increased the levels of DNA damage. Decreased tumor growth after combination therapy was maintained for 2 weeks without treatment, significantly increasing host survival. Therefore, combination treatment with CX-5461 and talazoparib is effective for HR-proficient tumors that are not suitable for monotherapy with PARP inhibitors, including AR-null CRPC. This expands the spectrum of CRPC that is sensitive to PARP inhibition." @default.
- W3194528984 created "2021-08-30" @default.
- W3194528984 creator A5005104377 @default.
- W3194528984 creator A5006713189 @default.
- W3194528984 creator A5010726074 @default.
- W3194528984 creator A5017625350 @default.
- W3194528984 creator A5020209705 @default.
- W3194528984 creator A5035230144 @default.
- W3194528984 creator A5042674529 @default.
- W3194528984 creator A5044516621 @default.
- W3194528984 creator A5045056236 @default.
- W3194528984 creator A5061483990 @default.
- W3194528984 creator A5064026461 @default.
- W3194528984 creator A5071409593 @default.
- W3194528984 creator A5078260365 @default.
- W3194528984 creator A5078921079 @default.
- W3194528984 creator A5080627838 @default.
- W3194528984 creator A5082144106 @default.
- W3194528984 creator A5089881929 @default.
- W3194528984 creator A5090641762 @default.
- W3194528984 date "2021-08-19" @default.
- W3194528984 modified "2023-10-15" @default.
- W3194528984 title "CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition" @default.
- W3194528984 cites W1578291413 @default.
- W3194528984 cites W1973268287 @default.
- W3194528984 cites W2006001375 @default.
- W3194528984 cites W2009007206 @default.
- W3194528984 cites W2019405732 @default.
- W3194528984 cites W2059586354 @default.
- W3194528984 cites W2095445604 @default.
- W3194528984 cites W2096439168 @default.
- W3194528984 cites W2100893053 @default.
- W3194528984 cites W2129104457 @default.
- W3194528984 cites W2147154862 @default.
- W3194528984 cites W2235405584 @default.
- W3194528984 cites W2262087934 @default.
- W3194528984 cites W2470218763 @default.
- W3194528984 cites W2477532021 @default.
- W3194528984 cites W2520780984 @default.
- W3194528984 cites W2539944286 @default.
- W3194528984 cites W2540537925 @default.
- W3194528984 cites W2548423821 @default.
- W3194528984 cites W2588135595 @default.
- W3194528984 cites W2588267243 @default.
- W3194528984 cites W2588930356 @default.
- W3194528984 cites W2593857065 @default.
- W3194528984 cites W2625362849 @default.
- W3194528984 cites W2743024582 @default.
- W3194528984 cites W2762381618 @default.
- W3194528984 cites W2789900707 @default.
- W3194528984 cites W2806421431 @default.
- W3194528984 cites W2810748925 @default.
- W3194528984 cites W2841858285 @default.
- W3194528984 cites W2883836317 @default.
- W3194528984 cites W2886477543 @default.
- W3194528984 cites W2915732659 @default.
- W3194528984 cites W2922329974 @default.
- W3194528984 cites W2922433043 @default.
- W3194528984 cites W2945629440 @default.
- W3194528984 cites W2947675852 @default.
- W3194528984 cites W2963279792 @default.
- W3194528984 cites W2973384337 @default.
- W3194528984 cites W2978095728 @default.
- W3194528984 cites W2981475131 @default.
- W3194528984 cites W2989894179 @default.
- W3194528984 cites W3002480029 @default.
- W3194528984 cites W3004754093 @default.
- W3194528984 cites W3008060424 @default.
- W3194528984 cites W3020771563 @default.
- W3194528984 cites W3030525997 @default.
- W3194528984 cites W3039594694 @default.
- W3194528984 cites W3039867072 @default.
- W3194528984 cites W3042118153 @default.
- W3194528984 cites W3093358877 @default.
- W3194528984 cites W3102515150 @default.
- W3194528984 cites W3132015612 @default.
- W3194528984 cites W3147725646 @default.
- W3194528984 doi "https://doi.org/10.1158/1535-7163.mct-20-0932" @default.
- W3194528984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34413130" @default.
- W3194528984 hasPublicationYear "2021" @default.
- W3194528984 type Work @default.
- W3194528984 sameAs 3194528984 @default.
- W3194528984 citedByCount "7" @default.
- W3194528984 countsByYear W31945289842021 @default.
- W3194528984 countsByYear W31945289842022 @default.
- W3194528984 countsByYear W31945289842023 @default.
- W3194528984 crossrefType "journal-article" @default.
- W3194528984 hasAuthorship W3194528984A5005104377 @default.
- W3194528984 hasAuthorship W3194528984A5006713189 @default.
- W3194528984 hasAuthorship W3194528984A5010726074 @default.
- W3194528984 hasAuthorship W3194528984A5017625350 @default.
- W3194528984 hasAuthorship W3194528984A5020209705 @default.
- W3194528984 hasAuthorship W3194528984A5035230144 @default.
- W3194528984 hasAuthorship W3194528984A5042674529 @default.
- W3194528984 hasAuthorship W3194528984A5044516621 @default.
- W3194528984 hasAuthorship W3194528984A5045056236 @default.
- W3194528984 hasAuthorship W3194528984A5061483990 @default.
- W3194528984 hasAuthorship W3194528984A5064026461 @default.